Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

In combination with JPI-547 and chemotherapy in patients with locally advanced/metastatic pancreatic cancer, Primary Objectives * To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). * To select the optimal combination chemotherapy based on the safety profile. Secondary Objectives * To assess the safety and toxicity. * To evaluate anti-tumor activity.